KIMBERLY-CLARK CORPORATION
At today's price, KIMBERLY-CLARK CORPORATION (KMB) is priced for -4.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
At $102.51 the price sits above every standard valuation family for Kimberly-Clark, the asset, earnings-power, peer-multiple, and forward-growth frames all land below it. The stock carries a quality premium the methods do not capture on their own. The defining event is the Kenvue acquisition, approved by shareholders on January 29, 2026, which folds Tylenol, Listerine, Neutrogena, and Band-Aid into the portfolio and reshapes Kimberly-Clark from a tissue-and-personal-care company into a broader
Is KMB overvalued? See what's priced in →
1,596 institutional managers reported holding KMB in 13F filings for the quarter ended 2026-03-31. Together they hold about 88% of the company; the top 10 hold 45%. 149 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 44.2M shares were sold short as of the 2026-06-15 count, about 13% of shares outstanding (9.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
KMB has cut its share count 1.6% over the past five years, spending $1.53B on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting), raised 16 years straight; the current rate is $5.04 a share annually. Cash returned over the past three years: $4.50B in dividends and $1.30B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at KMB over the trailing three years: 2024: 3 buys totaling $100k; 2025: 1 buy totaling $39k; 2026: 1 buy totaling $1.04M. 17 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
KMB's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-04-26 | +0.8% | -4.6% |
| 2023-07-26 | -3.9% | -7.8% |
| 2023-10-25 | -2.5% | +1.3% |
| 2024-02-09 | -0.3% | +3.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
KMB's latest 8-K filings: 2026-05-14 (items 5.07); 2026-05-05 (items 5.02); 2026-04-28 (items 2.02, 9.01); 2026-01-29 (items 5.07, 7.01, 9.01); 2026-01-27 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.